Guideline Updates

The NCCN has issued updated guideline recommendations for pancreatic adenocarcinoma that include additions to stent management and therapies for recurrent disease, among others.
The NCCN has made a number of revisions to the guideline for NSCLC, including updates to consolidation therapy for unresectable disease, first-line therapy for ALK-positive metastatic disease, and principles of molecular and biomarker analysis.
The NCCN has updated their guideline for small cell lung cancer to include new recommendations for surveillance, systemic therapy, and radiation therapy.
ASTRO, ASCO, and AUA developed a new guideline that suggests hypofractionated radiation therapy as an alternative to conventional radiation for early-stage prostate cancer.
The NCCN updated their guideline for CLL to include key information on tumor lysis syndrome prophylaxis and treatment with duvelisib for disease with or without del(17p)/TP53 mutation.
A new resource that offers patients and clinicians up-to-date information on neuroendocrine tumors for optimal decision-making has just been released by the NCCN.
Updated guidelines on antimicrobial prophylaxis for immunosuppressed cancer patients from the American Society of Clinical Oncology and the Infectious Disease Society of America now include recommendations on antiviral prophylaxis and vaccination.
The American Society of Clinical Oncology has endorsed the College of American Pathologists evidence-based guideline on testing, application, interpretation, and reporting of human papillomavirus and surrogate marker tests in head and neck carcinomas.
The NCCN has released updated guidelines for prostate cancer, including the addition of a combination therapy, systemic therapy for castration-resistant therapy, and a principle of androgen deprivation therapy.
The American Society of Clinical Oncology released an update to the guideline for systemic therapy for patients with HER2-positive metastatic breast cancer.